StimLabs

06/12/2024

https://stimlabs.com/irb-campstim-dfu/

StimLabs announces IRB approval for CAMPSTIM, the largest RCT trial to demonstrate the efficacy of multiple placental-based tissue products for treatment of hard-to-heal DFUs. CAMPSTIM will evaluate at least four CAMPs (Enverse, Revita, Relese and Cogenex) and enroll 272 patients in the US.